ArticleJournal of clinical medicine2022
Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Pretreatment Prediction of Tumor Recurrence in Breast Cancer After Neoadjuvant Systemic Therapy Using Machine Learning With Clinical and CT Radiomics Features.The Kaohsiung journal of medical sciences · 2026Article
- Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Perineural invasion and risk of lymph node metastasis in early-stage operable breast cancer: a large-scale propensity-matched cohort study and meta-analysis.Therapeutic advances in medical oncology · 2026Article
- Review
- Genomic Insights Into Early Relapsed Breast Cancer: Prognostic Challenges and Mutation Landscape.OncoTargets and therapy · 2025Article
- Delving into the Role of α-Smooth Muscle Actin as a Predictive Biomarker of Early Recurrence in Invasive Ductal Adenocarcinoma of Breast.Iranian journal of pathology · 2024Article
- Increased Nerve Density Adversely Affects Outcome in Oral Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant.Cureus · 2023Article
- Risk of Breast Cancer Progression after Treatment in the Western Region of Saudi Arabia.Breast cancer : basic and clinical research · 2023Article
- Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach.Polymers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we aimed to assess clinicopathological factors affecting early and late recurrences in patients with operable breast cancer. Patients with early (≤5 years) and late (>5 years) recurrences were assessed. Prognostic factors for disease-free survival (DFS) were also evaluated in patients with recurrence. A total of 854 patients were included. There were 432 and 205 patients in the early and late recurrence groups, respectively. In multivariate analyses, HER2+ disease, lymph node metastasis, lymphovascular invasion (LVI), and high tumor grade were associated with increased risk of early recurrence, while HER2+ disease and LVI were associated with decreased risk of late recurrence. In multivariate analyses, presence of HER2+ disease and triple-negative breast cancer (TNBC) were poor prognostic factors for DFS in patients with early recurrence. Presence of LVI and perineural invasion (PNI) were poor prognostic factors for DFS in patients with late recurrence. Molecular subtypes and LVI were effective on the early and late recurrences. However, lymph node positivity and grade were only associated with the early recurrence. After 5 years, LVI and PNI were the prognostic factors for DFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.